Subsequent Events - Additional Information (Details) - Royalty Pharma Agreement - Subsequent Event $ in Millions |
Nov. 09, 2022
USD ($)
|
|---|---|
| Subsequent Event [Line Items] | |
| Cash received as due under collaboration agreement | $ 250.0 |
| Milestone payment receivable | 160.0 |
| Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial | 50.0 |
| Milestone payment receivable upon FDA approval | 50.0 |
| Milestone payment receivable upon receipt of royalty payments | 60.0 |
| Royalty payment threshold | 70.0 |
| Maximum | |
| Subsequent Event [Line Items] | |
| Initial transaction price | $ 410.0 |